ReviewNatural products and bioprospecting2026
Distribution and bioactivities of tirucallane-type triterpenoids from Meliaceae family.
Review in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tirucallane-type triterpenoids are one of the most structurally diverse classes of secondary metabolites in Meliaceae family, which is predominantly distributed across tropical and subtropical regions. A total of 373 tirucallane derivatives have been reported between 1967 and 2025, from 48 species belonging to 17 genera. These compounds were isolated from different plant parts, including bark, stem bark, roots, leaves, fruits, twigs, seeds, and aerial tissues. Therefore, this review aims to integrate current reports on tirucallane-type triterpenoids from 17 Meliaceae genera, emphasizing structural complexity, taxonomic occurrence, and pharmacological relevance to guide future chemotaxonomic and drug discovery efforts. Literature collection was performed through Google Scholar, Reaxys, PubMed, and SciFinder. The results showed that based on the structural characteristics, tirucallane derivatives were categorized into intact, seco, heteroatom-substituted, degraded, and highly rearranged, with the intact subgroup being the most abundant. Furthermore, tirucallane derivatives have a broad spectrum of biological properties, including cytotoxic, antimicrobial, antiplasmodial, antidiabetic, anti-inflammatory, immunomodulatory, FXR agonistic, and insecticidal effects, indicating significant potential therapeutic value. Among the reported compounds, laxiracemosin E (361) showed the strongest anticancer potential with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.